The estimated Net Worth of Raymond J Land is at least $1.84 Million dollars as of 12 May 2021. Mr. Land owns over 2,000 units of Anika Therapeutics stock worth over $192,860 and over the last 19 years he sold ANIK stock worth over $1,449,354. In addition, he makes $199,980 as Independent Director at Anika Therapeutics.
Sign up
Mr. Land ANIK stock SEC Form 4 insiders trading
Raymond has made over 15 trades of the Anika Therapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of ANIK stock worth $85,200 on 12 May 2021.
The largest trade he's ever made was selling 8,914 units of Anika Therapeutics stock on 27 February 2014 worth over $387,492. On average, Raymond trades about 1,511 units every 127 days since 2006. As of 12 May 2021 he still owns at least 7,953 units of Anika Therapeutics stock.
You can see the complete history of Mr. Land stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Raymond Land biography
Raymond J. Land CPA serves as Independent Director of the Company. He also serves as chairman of the Board of Directors and interim Chief Financial Officer of BioAmber, Inc., a publicly traded company developing chemicals from renewable feedstocks, and a director and chairman of the Audit Committee of Mountain View Pharmaceuticals, Inc., a privately held company specializing in biopharmaceuticals. From 2008 through 2010, Mr. Land served as the Senior Vice President and Chief Financial Officer of Clarient, Inc., an advanced molecular diagnostics company. From June 2007 to June 2008, he was the Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., a venture capital firm. Prior to Safeguard Scientifics, Inc., Mr. Land held executive management and Chief Financial Officer positions at Medcenter Solutions, Inc., a pharmaceutical marketing company where he was also a board member, and Orchid Cellmark, a provider of DNA testing services. Mr. Land previously served as Senior Vice President and Chief Financial Officer for Genencor International, Inc., a biotechnology company focusing on bioproducts and healthcare, from 1997 until its acquisition in April 2005. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for West Pharmaceutical Services, Inc. Previously, Mr. Land was with Campbell Soup Company, Inc. where for nine years he held increasingly senior financial positions and also served as General Manager of a frozen food division. Prior to joining Campbell Soup, he was with Coopers and Lybrand for nine years. Mr. Land is a retired Certified Public Accountant and has a B.S. degree in accounting and finance from Temple University.
What is the salary of Raymond Land?
As the Independent Director of Anika Therapeutics, the total compensation of Raymond Land at Anika Therapeutics is $199,980. There are 9 executives at Anika Therapeutics getting paid more, with James Loerop having the highest compensation of $1,479,630.
How old is Raymond Land?
Raymond Land is 75, he's been the Independent Director of Anika Therapeutics since 2006. There are 1 older and 16 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
Insiders trading at Anika Therapeutics
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia, and Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
What does Anika Therapeutics do?
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
What does Anika Therapeutics's logo look like?
Complete history of Mr. Land stock trades at Anika Therapeutics and Safeguard Scientifics
Anika Therapeutics executives and stock owners
Anika Therapeutics executives and other stock owners filed with the SEC include:
-
James Loerop,
Executive Vice President - Business Development and Strategic Planning -
Thomas Finnerty,
Executive Vice President of Human Resources -
Dr. Cheryl Renee Blanchard Ph.D.,
Pres, CEO & Director -
David Colleran,
Exec. VP, Gen. Counsel & Corp. Sec. -
James Loerop,
Exec. VP of Bus. Devel. & Strategic Planning -
Michael L. Levitz,
Exec. VP, CFO & Treasurer -
Thomas M. Finnerty,
Exec. VP of HR -
Joseph Bower,
Independent Chairman of the Board -
Jeffery Thompson,
Independent Director -
Raymond Land,
Independent Director -
Glenn Larsen,
Independent Director -
Cheryl Blanchard,
President, Chief Executive Officer, Director -
Susan Vogt,
Independent Director -
Dr. Cheryl R. Blanchard,
Pres, CEO & Director -
Stephen Richard,
Independent Director -
John Henneman,
Independent Director -
David Colleran,
Executive Vice President, General Counsel, Secretary -
Michael Levitz,
Chief Financial Officer, Executive Vice President, Treasurer -
Anne Nunes,
VP of Operations -
Bart Bracy,
VP of Sales & Marketing of Americas -
James Chase,
Sr. VP of International Sales & Marketing -
Charles Sherwood III,
VP & Corp. Legal Counsel -
Mark Namaroff,
Exec. Director of Investor Relations & Corp. Communications -
Alexei Goraltchouk,
Sr. VP of Operations & Project Management -
Richard Hague,
Chief Commercial Officer -
Edward S. Ahn,
Chief Tech. & Strategy Officer -
Charles H Sherwood,
President and CEO -
Sylvia Cheung,
Chief Financial Officer -
Steve E Wheeler,
Director -
Dana M. Alexander,
Chief Operations Officer -
Stephen R. Mascioli,
Chief Medical Officer -
John C Moran,
Director -
Joseph G Darling,
President and CEO; Director -
Gary P Fischetti,
Director -
Sheryl L Conley,
Director -
John W Jr Sheets,
Chief Scientific Officer -
Farmaceutici S.P.A. Fidia,
10% owner -
Peter Litman,
VP, Business Development -
William J Knight,
Chief Financial Officer -
Harvey S Sadow,
Director -
William Mrachek,
V.P., Human Resources -
Samuel F Mckay,
Director -
Eugene A Davidson,
Director -
Francesco J Luppino,
Chief Operating Officer -
Carol A Barnett,
Chief Commercial Officer -
Kevin W Quinlan,
Chief Financial Officer -
Constance H Garrison,
VP Reg.,Clinical & Qlty. Sys. -
James E O Neill,
Chief Accounting Officer -
Carol A Toth,
Vice President, R & D -
Elizabeth Chen,
Sr. VP Mktg. & Bus. Dev. -
Anne Nunes,
SVP, Chief Operations Officer -
Stephen D. Griffin,
EVP, CFO and Treasurer -
Joseph H Capper,
Director -
William R Jellison,
Director